UCARTCS1

UCARTCS1 is an allogeneic, off-the-shelf, gene-edited CAR T-cell therapy developed for the treatment of multiple myeloma. It is engineered from healthy donor T-cells using TALEN gene-editing technology to knock out the CS1 (SLAMF7) gene before introducing a chimeric antigen receptor (CAR) targeting CS1/SLAMF7, which is highly expressed on multiple myeloma cells. The product was designed to provide a readily available cell therapy option without the need for patient-specific manufacturing and to reduce risks of graft-versus-host disease by eliminating endogenous T-cell receptors. UCARTCS1 entered clinical development as the first allogeneic CAR-T therapy for multiple myeloma but its development was discontinued in 2023 due to slow trial enrollment and resource constraints[1][2][4][6].

Brand names

UCARTCS1UCARTCS-1UCARTCS 1

Other names

cs1 car-t cellscs-1 car-t cellscs 1 car-t cellsslamf7 car-t cellsslamf-7 car-t cellsslamf 7 car-t cellscd319 car-t cellscd-319 car-t cellscd 319 car-t cells